EFFICIENCY OF SYSTEMIC THERAPY FOR STAGE IV RENAL CELL CARCINOMA IN TERMS OF PROGNOSTIC FACTORS

Download full text PDF
Issue: 
8
Year: 
2016

A. Poluyanchik N.N. Aleksandrov Republican Research and Practical Center for Oncology and Medical Radiology, Minsk, Republic of Belarus

This investigation has evaluated the efficiency of treatment and identified prognostic factors for adjusted survival rates in patients with disseminated kidney cancer treated at the Republican Research and Practical Center for Oncology and Medical Radiology (Minsk) in 1999 to 2011. A prognostic classification has been elaborated for disseminated renal cell carcinoma, in accordance with which patients with less than 2 risk factors are classified into a low-risk group, those with 3-4 and more than 4 risk factors are into medium- and high-risk groups, respectively.
Keywords: 
oncology
renal cell carcinoma
prognostic factors
adjusted survival rates
risk factors
risk groups

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Aleksandrov N.N., Fradkin S.Z. Gipertermija–perekislenie v kom pleksnom lechenii zlokachestvennyh novoobrazovanij: Nauch. obzor. Pod red. N.E. Savchenko / M., 1976; 110 s.
  2. Aleksandrov N.N., Savchenko N.E., Fradkin S.Z. Primenenie giperter mii i giperglikemii pri lechenii zlokachestvennyh opuholej / M.: Meditsina, 1980; 256 s.
  3. Okeanov A.E., Moiseev P.I., Levin L.F. Zlokachestvennye novoobrazo vanija v Belarusi, 2001–2012. Pod red. O.G. Sukonko / Minsk: RNPTs OMR, 2013; 373 s.
  4. Landis S., Murray T., Bolden S. et al. Cancer statistics: 1999 // CA Cancer J. Clin. – 1999; 49: 8–31.
  5. Pantuck A., Zisman A., Belldegrun A. The changing natural history of renal cell carcinoma // J. Urol. – 2001; 166: 1611–23
  6. Motzer R., Mazumdar M., Bacik J. et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma // J. Clin. Oncol. – 1999; 17: 2530–40.
  7. Heng D. et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study // J. Clin. Oncol. – 2009; 27 (34): 5794–9.
  8. Isbarn H., Karakiewicz P. Predicting cancer-control outcomes in patients with renal cell carcinoma // Curr. Opin Urol. – 2009; 19: 247–57.
  9. Cindolo L., de la Taille A., Messina G. et al. A preoperative clinical prognostic model for non-metastatic renal cell carcinoma // BJU Int. – 2003; 92: 901–5.
  10. Motzer R., Bukowski R., Figlin R. et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma // Cancer. – 2008; 113: 1552–8.
  11. Motzer R., Bacik J., Murphy B. et al. Interferon-alfa as a comparative treatment for clinical trials of newtherapies against advanced renal cell carcinoma // J. Clin. Oncol. – 2002; 20: 289–96.
  12. Kim H., Hong M., Kim K. et al. Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles // Oncology. – 2011; 80: 395–405.
  13. Coppin C., Porzsolt F., Autenrieth M. et al. Immunotherapy for advanced renal cell cancer // Cochrane Database System. Rev. – 2000; Issue 3: CD001425.
  14. Hudes G., Carducci M. et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma // N. Engl. J. Med. – 2007; 356 (22): 2271–81.